Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzhe

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of low-dose interleukin 2 (ld IL-2) in 8 patients with Alzheimer’s disease (AD). The academic study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.The additional cl...

Related Keywords

Houston ,Texas ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Americans ,Stanley Appel ,David Snyder ,Nasdaq ,Alzheimer Association International Conference ,Alzheimer Association ,Centers For Disease ,Gates Foundation ,Coya Therapeutics Inc ,Houston Methodist ,Mini Mental State Examination ,Disease Assessment Scale ,Cognitive Subscale ,Clinical Dementia Rating Sum ,Coya Therapeutics ,Association International Conference ,Houston Methodist Hospital ,Scientific Advisory Board ,Disease Control ,